• #1064517
  • 392
  • Glaxo Smith Kline #58160095509

Menveo® Meningitis Vaccine Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Preservative Free 10 mcg - 5 mcg / 0.5 mL Injection Single Dose Vial 0.5 mL

MENVEO VACCINE, SDV 10-5MG/0.5ML (5/CT)

Features
  • MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. MENVEO is approved for use in persons 2 months through 55 years of age
  • MENVEO is supplied in two vials that must be combined prior to administration: reconstitute the MenA lyophilized conjugate vaccine component with the MenCYW-135 liquid conjugate vaccine component immediately before administration
  • More …
  Log In to Order
or

Product Specifications


McKesson #1064517
Manufacturer #58160095509
BrandMenveo®
ManufacturerGlaxo Smith Kline
Country of OriginUnknown
Alternate Manufacturer Number3677333
ApplicationMeningitis Vaccine
Container TypeSingle Dose Vial
Dosage FormInjection
Generic Drug Code28272
Generic Drug NameMeningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Preservative Free
NDC Number58160-0955-09
Product DatingMcKesson Acceptable Dating: we will ship >= 60 days
Storage RequirementsRequires Refrigeration
Strength10 mcg - 5 mcg / 0.5 mL
TypeIntramuscular
UNSPSC Code51201610
Volume0.5 mL
Features
  • MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. MENVEO is approved for use in persons 2 months through 55 years of age
  • MENVEO is supplied in two vials that must be combined prior to administration: reconstitute the MenA lyophilized conjugate vaccine component with the MenCYW-135 liquid conjugate vaccine component immediately before administration
More Information

Professionals Also Viewed